From Chronodisruption to Sarcopenia: The Therapeutic Potential of Melatonin

Biomolecules. 2023 Dec 12;13(12):1779. doi: 10.3390/biom13121779.

Abstract

Sarcopenia is an age-related condition that involves a progressive decline in muscle mass and function, leading to increased risk of falls, frailty, and mortality. Although the exact mechanisms are not fully understood, aging-related processes like inflammation, oxidative stress, reduced mitochondrial capacity, and cell apoptosis contribute to this decline. Disruption of the circadian system with age may initiate these pathways in skeletal muscle, preceding the onset of sarcopenia. At present, there is no pharmacological treatment for sarcopenia, only resistance exercise and proper nutrition may delay its onset. Melatonin, derived from tryptophan, emerges as an exceptional candidate for treating sarcopenia due to its chronobiotic, antioxidant, and anti-inflammatory properties. Its impact on mitochondria and organelle, where it is synthesized and crucial in aging skeletal muscle, further highlights its potential. In this review, we discuss the influence of clock genes in muscular aging, with special reference to peripheral clock genes in the skeletal muscle, as well as their relationship with melatonin, which is proposed as a potential therapy against sarcopenia.

Keywords: Bmal1; aging; chronodisruption; clock genes; inflammaging; melatonin; mitochondria; oxidative stress; sarcopenia; skeletal muscle.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / metabolism
  • Humans
  • Melatonin* / metabolism
  • Melatonin* / pharmacology
  • Melatonin* / therapeutic use
  • Muscle, Skeletal / metabolism
  • Oxidative Stress
  • Sarcopenia* / drug therapy
  • Sarcopenia* / metabolism

Substances

  • Melatonin